ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -176.91% | -165.07% | -20.47% | 62.02% | 90.94% |
| Total Depreciation and Amortization | -- | -- | 100.00% | -83.65% | -58.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,335.51% | 1,891.18% | 45.73% | -93.87% | -99.13% |
| Change in Net Operating Assets | -30.86% | 56.88% | 449.21% | 928.36% | 25.50% |
| Cash from Operations | 24.91% | 31.98% | 34.94% | 45.59% | 30.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -46.95% | -68.63% | -40.09% | -63.97% | -82.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -117.92% | 360.00% | 242.15% | 200.27% | 151.28% |
| Cash from Financing | -44.38% | -37.67% | -17.23% | -45.46% | -41.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.07% | 11.06% | 127.83% | 56.59% | -155.87% |